Anbio Biotechnology (NNNN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Anbio Biotechnology (NNNN) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.01 of bullish evidence against -0.26 bearish.

Anbio Biotechnology last closed at $4.83, -12.97% on the session.

Against the IVW growth benchmark the position is -13.89% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

16 graded predictions for NNNN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Anbio Biotechnology is classified under Health Care / Biotechnology, with a market capitalisation of $243.60M.

StockMap tracks Anbio Biotechnology as the 214th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Anbio Biotechnology ranks 197th of 344 in the group, against a group median of -0.21.